San Francisco Biotechnology Network

SFBN Feed: Opinion: Novel coronavirus 2019-nCoV exposes a flaw in the Nagoya Protocol: The Nagoya Protocol has the laudable aim of giving each country sovereignty over its biological resources. But this could ... #BayArea #Biotechhttp://tinyurl.com/sk9jyna 

SFBN Feed: Bill Gates pitches in on coronavirus R&D and containment efforts with $100M commitment: The Gates Foundation has signed up to take a role in the growing public-private response to a ... #BayArea #Biotechhttp://tinyurl.com/tpxguaw 

SFBN Feed: EMA, FDA and WHO prep for new coronavirus treatments, IVDs: Following the World Health Organization’s (WHO) determination last week that the spread of the novel coronavirus (2019-nCoV) from ... #BayArea #Biotechhttp://tinyurl.com/ugxozz4 

SFBN Feed: After peanut allergy drug approval, Peninsula biotech munches sweet $200M deal: Aimmune Therapeutics Inc. has gobbled up a $200 million investment from Swiss food and drink conglomerate Nestlé ... #BayArea #Biotechhttp://tinyurl.com/vx5kjzh 

SFBN Feed: Real-world data get real dollars: GV, Bain help infuse $100M into Verana Health as it moves beyond registry: As the application of real-world data in clinical practice and drug development becomes ... #BayArea #Biotechhttp://tinyurl.com/w8ao8q2 

SFBN Feed: Verana Health Acquires PYA Analytics; Announces $100 Million Financing Round Led by GV: SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Verana Health, a technology company that is curating and analyzing ... #BayArea #Biotechhttp://tinyurl.com/ul6ff2l 

SFBN Feed: Yes, Gilead CEO Daniel O’Day is ready to ink some deals. No, you won’t see him sweat it: A bevy of analysts turned out for Gilead’s Q4 call Tuesday night looking for some of the old sizzle ... #BayArea #Biotechhttp://tinyurl.com/t9k5w87 

SFBN Feed: China researchers tout in vitro data for Gilead's antiviral against Wuhan virus — which they are trying to patent: There’s no definitive proof yet that Gilead’s remdesivir works as ... #BayArea #Biotechhttp://tinyurl.com/tqp2x8k 

SFBN Feed: Chatbots are screening for the new coronavirus — and turning up cases of the flu: If the #coronavirus spreads more widely in the U.S., medical chatbot companies could be poised to play a more ... #BayArea #Biotechhttp://tinyurl.com/w8ah67u 

SFBN Feed: Alkahest Initiates a Phase 2 Clinical Trial of AKST4290 in Parkinson’s Disease with Funding from The Michael J. Fox Foundation: SAN CARLOS, Calif., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Alkahest, ... #BayArea #Biotechhttp://tinyurl.com/suav66v 

SFBN Feed: Kezar Announces Closing of $56.8 Million Public Offering of Common Stock and Pre-Funded Warrants: SOUTH SAN FRANCISCO, Calif., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, ... #BayArea #Biotechhttp://tinyurl.com/uwufa8h 

SFBN Feed: 10x Genomics to Report Fourth Quarter and Full Year 2019 Financial Results on February 18, 2020: PLEASANTON, Calif., Feb. 04, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced it ... #BayArea #Biotechhttp://tinyurl.com/ryjpmc4 

SFBN Feed: RAPT Therapeutics Announces Proposed Offering of Common Stock: SOUTH SAN FRANCISCO, Calif., Feb. 04, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage ... #BayArea #Biotechhttp://tinyurl.com/wslkr3b 

SFBN Feed: Why a biotech landlord is expanding to megacampuses: Its potential 1.7 million-square-foot campus in South San Francisco matches the biotech industry's growth. Click to view original post #BayArea #Biotechhttp://tinyurl.com/ur95rhr 

SFBN Feed: Vertily, Santen See Opthalmology Opportunity Via New Joint Venture: Verily, the life sciences spinout of Google parent Alphabet, has inked a deal with a Japanese ophthalmology company to develop ... #BayArea #Biotechhttp://tinyurl.com/trnx5qw 

SFBN Feed: Walgreens settles lawsuit over fake pharmacist at local stores: Walgreens settled a lawsuit Monday, filed by the district attorneys of Alameda and Santa Clara Counties, who had accused the company ... #BayArea #Biotechhttp://tinyurl.com/sgllmu4 

SFBN Feed: HIV vaccine remains Holy Grail as Sanofi/GSK regimen disappoints in large study: An HIV vaccine regimen comprising experimental components supplied by Sanofi and GlaxoSmithKline has been declared ... #BayArea #Biotechhttp://tinyurl.com/u5d5uah 

SFBN Feed: Bay Area biotech CEO convicted of siphoning off $2.6M to buy a home; Merck wins Alzheimer's nod for insomnia pill: → A Bay Area biotech exec has been convicted of defrauding his own ... #BayArea #Biotechhttp://tinyurl.com/r8c8beu 

SFBN Feed: Regeneron joins the hunt for antibodies to fight a brewing pandemic as researchers whip up new trials for antivirals: Count Regeneron as the latest big biopharma company to pitch in on finding a ... #BayArea #Biotechhttp://tinyurl.com/wv3yz8h